N4 Pharma plc (AIM: N4P)*: Business and operational updateAvacta Group plc (AIM: AVCT): Faridoxorubicin (AVA6000) Phase Ib cohort demonstrated clinically meaningful tumour shrinkage in patients with salivary gland cancersGENinCode plc (AIM: GENI): CARDIO inCode-Score® distribution with Sohin Genetics, Mexico
17 Dec 2025
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
SP Angel Healthcare Conditions
- Published:
17 Dec 2025 -
Author:
Vadim Alexandre | Greg Pave -
Pages:
4 -
N4 Pharma plc (AIM: N4P)*: Business and operational updateAvacta Group plc (AIM: AVCT): Faridoxorubicin (AVA6000) Phase Ib cohort demonstrated clinically meaningful tumour shrinkage in patients with salivary gland cancersGENinCode plc (AIM: GENI): CARDIO inCode-Score® distribution with Sohin Genetics, Mexico